Colorectal Cancer Cell Articles & Analysis
4 news found
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed ...
(Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announces that Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100, at the Annual Meeting of ...
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, today announces that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial evaluating its investigational imaging agent SGM-101 in patients undergoing ...
BySurgiMab
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach designed to improve cancer surgery and clinical outcomes for patients, today announces that the first surgical procedure was carried out in a pivotal Phase 3 clinical trial of the Company's lead product, SGM-101, in a patient with colorectal ...
BySurgiMab